Caribou Biosciences to Present at Upcoming Investor Conference
Caribou Biosciences (Nasdaq: CRBU) has announced that CEO Rachel Haurwitz will participate in the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, at 8:00 am PT. The event will feature a fireside chat and will be available for live streaming on Caribou's website, with an archived version accessible for 30 days post-event. Caribou is focused on developing advanced CRISPR-based therapies for severe diseases, utilizing its proprietary Cas12a chRDNA technology for precise genome editing.
- None.
- None.
BERKELEY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will participate in a fireside chat at the following upcoming investor conference in May:
- BofA Securities 2022 Healthcare Conference
Tuesday, May 10th, at 8:00 am PT
A webcast of the fireside chat presentation will be accessible via Caribou’s website on the Events page. The archived webcast will be available on the Caribou website for 30 days after the event.
About Caribou’s Novel Next-Generation CRISPR Platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays” that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its proprietary Cas12a chRDNA technology, enables superior precision to develop cell therapies that are specifically engineered for enhanced persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of patients with hematologic malignancies and solid tumors.
Follow us @CaribouBio and visit www.cariboubio.com.
“Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
| Caribou Biosciences, Inc. Contacts: |
| Amy Figueroa, CFA |
| Investor Relations and Corporate Communications |
| afigueroa@cariboubio.com |
| Investors and Media: |
| Elizabeth Wolffe, Ph.D., and Sylvia Wheeler |
| Wheelhouse LSA |
| lwolffe@wheelhouselsa.com |
| swheeler@wheelhouselsa.com |
FAQ
When is Caribou Biosciences' fireside chat at the BofA Securities 2022 Healthcare Conference?
Where can I watch the Caribou Biosciences fireside chat?
How long will the archived webcast of the Caribou Biosciences event be available?
What technology does Caribou Biosciences use for genome editing?
What type of therapies is Caribou Biosciences developing?
